Update on Chronic Fatigue Syndrome Part 2: Uniting Compassion, Attention and Innovation to treat ME/CFS
This ME/CFS CME module is designed to help medical providers recognize the major treatable aspects of ME/CFS and design a common sense management plan in the absence of formal treatment guidelines. Focus will be on the core diagnostic criteria and common co-morbid conditions amenable to treatment.
NOTE: ICD-10 Coding recommendations: Once a diagnosis of ME/CFS is established the proper ICD-10 code is G93.3 (post-viral fatigue, myalgic encephalomyelitis)
Earns: .75 CME credit
Bateman Horne Center is a 501(c)3 nonprofit clinic and research center.
BHC and Lucinda Bateman MD are conducting a phase I/II clinical trial of an investigational drug for ME/CFS made by Cortene pharmaceuticals. It will not be discussed in this presentation.
BHC and Lucinda Bateman MD are contracted with Lundbeck pharmaceutical as a site for the post label marketing study of a drug for neurogenic orthostatic hypotension. It will not be discussed in this presentation.
Off label use of medications will be discussed in the presentation and described as such.
The MSMS meeting planner, Beth Elliott, does not have relevant financial relationships.
Statement of Accreditation:
The Michigan State Medical Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Michigan State Medical Society designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Lucinda Bateman, MD, Founder & Medical Director, Bateman Horne Center